home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

A Clever Treatment For Prostate Cancer

  November, 4 2000 3:16
your information resource in human molecular genetics
Some forms of prostate cancer thrive on the male hormone androgen, and thus a form of prostate cancer treatment is to use compounds that block androgen's effects to stop the growth of tumorous cells. However, there is presently no treatment available to extend the survival of men with prostate cancer that is androgen-refractory. And unfortunately, the doses of chemotherapeutic drugs required to overcome androgen-refractory prostate cancer are so large that they are prohibited by their toxicity.

Now, scientists at Merck Research Laboratories in Pennsylvania (Nature Medicine, 01 Nov 2000) have devised a way to increase the dose of one chemotherapeutic drug, doxorubicin to such a level that it can be tolerated by prostate cancer patients and also be high enough to destroy cancerous cells.

Raymond Jones and colleagues attached doxorubicin to a peptide in such a way that the linking bond can be cleaved by prostate specific antigen (PSA), which is over-expressed in prostate cancer tissue.

When the doxorubucin conjugate was tested in mice, it was found to be 15 times more potent than ordinary doxorubucin at blocking the growth of human prostate cancer tumors. It was also less toxic to ordinary tissue because it is activated only in the presence of PSA, which is largely confined to the prostate gland. The authors conclude, "These experiments support the use of PSA-hydrolyzable peptide conjugation for the treatment of prostate cancer in man."

Dr. Raymond Jones:
Merck Research Laboratories
Bldg. 16 Room 310
PO Box 4
West Point, PA 19486
Tel.: 215-652-7637
Email: raymond_jones@merck.com

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.